A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well known. We prospectively compared the outcomes...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ferrata Storti Foundation
2016-08-01
|
| Serier: | Haematologica |
| Online adgang: | https://haematologica.org/article/view/7793 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
